Login to Your Account

Pieris, Astrazeneca ink $2.1B pact for respiratory disease

By Cormac Sheridan
Staff Writer

Wednesday, May 3, 2017

DUBLIN – Pieris Pharmaceuticals Inc. has laid down a big marker for its credentials in respiratory disease through an alliance with Astrazeneca plc under which it is receiving $57.5 million in up-front and near-term milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription